



Universiteit
Leiden
The Netherlands

Clinical pharmacological aspects of mitochondrial function in muscle

Diemen, M.P.J. van

Citation

Diemen, M. P. J. van. (2021, January 27). *Clinical pharmacological aspects of mitochondrial function in muscle*. Retrieved from <https://hdl.handle.net/1887/3134870>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3134870>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3134870> holds various files of this Leiden University dissertation.

Author: Diemen, M.P.J. van

Title: Clinical pharmacological aspects of mitochondrial function in muscle

Issue Date: 2021-01-27

BRAIN BIO-ENERGETIC STATE DOES NOT CORRELATE TO MUSCLE MITOCHONDRIAL FUNCTION IN HUNTINGTON'S DISEASE

Published Journal of Huntington's Disease 2020; 2020;9(4):335-344. DOI: 10.3233/JHD-200413

Marcus PJ van Diemen, MD¹ ; Ilse van Beelen, BSc¹ ; Ellen P Hart, PhD¹ ; Pieter W Hameeteman, MSc¹
Emma M Coppen, MD⁴ ; Jessica Y Winder, MD⁴ ; Jonas den Heijer, MD¹ ; Matthijs Moerland, PhD¹
Hermien Kan, PhD² ; Jeroen van der Grond, PhD³ ; Andrew Webb, PhD² ; Raymund AC Roos, MD, PhD⁴
Geert Jan Groeneveld, MD, PhD^{1,5*} ; 1. Centre for Human Drug Research, Leiden, NL ; 2. Gorter Centre for high-field MRI, Leiden University Medical Center, Leiden, NL ; 3. Radiology Research Center, Department of Radiology, Leiden University Medical Center, Leiden, NL
4. Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands ; 5. Department of Anesthesiology, Leiden University Medical Center, Leiden, nl ; * corresponding author: ggroeneveld@chdr.nl

BACKGROUND Huntington's disease (HD) is a neurodegenerative disease with cognitive, motor and psychiatric symptoms. A toxic accumulation of misfolded mutant huntingtin protein (HTT) induces mitochondrial dysfunction, leading to a bioenergetic insufficiency in neuronal and muscle cells. Improving mitochondrial function has been proposed as an opportunity to treat HD, but it is not known how mitochondrial function in different tissues relates. We explored associations between central and peripheral mitochondrial function in a group of mild to moderate staged HD patients.

METHODS We used phosphorous Magnetic Resonance Spectroscopy (31P-MRS) to measure mitochondrial function *in vivo* in the calf muscle (peripheral) and the bio-energetic state in the visual cortex (central). Mitochondrial function was also assessed *ex vivo* in circulating peripheral blood mononuclear cells (PBMCs). Clinical function was determined by the Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Pearson correlation coefficients were computed to assess the correlation between the different variables.

RESULTS We included 23 manifest HD patients for analysis. There was no significant correlation between central bio-energetics and peripheral mitochondrial function. Central mitochondrial function at rest correlated significantly to the UHDRS total motor score ($R=-0.45$ and -0.48), which increased in a subgroup with the largest number of CAG repeats.

DISCUSSION We did not observe a correlation between peripheral and central mitochondrial function. Central, but not peripheral, mitochondrial function correlated to clinical function. Muscle mitochondrial function is a promising biomarker to evaluate disease-modifying compounds that improve mitochondrial function, but Huntington researchers should use central mitochondrial function to demonstrate proof-of-pharmacology of disease-modifying compounds

BACKGROUND

Huntington's disease (HD) is a progressive neurodegenerative disease, characterized by motor, cognitive and psychiatric signs and symptoms, caused by an inherited CAG-repeat (glutamine) expansion in the gene coding for the huntingtin (HTT) protein, which leads to misfolding.¹ Accumulation of misfolded HTT is toxic for cells and results in the characteristic neuronal loss of the striatal region in the brain.¹ The exact mechanism for this degeneration is not fully understood, but evidence from HD mouse models points towards changes in metabolism and/or bioenergetics (reviewed by Polyzos *et al.* in).² Mitochondria supply over 90% of cells' energy needs, are especially sensitive to accumulation of mutant HTT and disturbances of mitochondrial function are suspected to play an important role in the pathogenesis of the disease.³ Observed in HD mouse models, mitochondrial dysfunction occurs during the later stages of the disease.⁴⁻⁶ Striatal cells have a very high energy demand and heavily rely on well-functioning mitochondria.⁷ Therefore, it is likely that a disturbance in mitochondrial bio-energetics within striatal cells can lead to neuronal loss. A similar mechanism of mitochondrial dysfunction is thought to be involved in Parkinson's disease (PD), another neurodegenerative disease, which results from neuronal loss of the also high energy demanding cells that form the substantia nigra. In animals, HD and PD phenotypes, including pathology in the brain and disease specific symptoms, can be induced by administering mitochondrial toxins.⁸⁻¹¹ Mutant HTT has indeed been shown to localize to mitochondria¹²⁻¹⁴ and to interact with the mitochondrial protein import machinery in striatal cells in a mutant HTT knock-in mouse model and in postmortem brain sections of patients with grade 2 HD.¹⁵ Furthermore, mutant HTT directly inhibits mitochondrial protein import *in vitro*, triggering mutant HTT induced cell death of primary neurons.¹⁵ In patients with HD, several studies have observed a decreased mitochondrial function when compared to healthy volunteers: mitochondrial function in the calf muscle and circulating lymphoblasts and the bio-energetic state of the visual cortex.¹⁶⁻¹⁸ Accumulation of mutant HTT is not specific for the striatum, but also occurs in cells outside the brain, such as muscle cells. Using immunohistology, myofibers of HD patients were found to stain intensely for granules of HTT, whereas myofibers of healthy controls only contained a few granules, which correlated to mitochondrial function.¹⁶ This suggests mitochondria as a pharmacological target to treat HD. Indeed, several clinical trials have targeted mitochondrial dysfunction in an attempt to treat HD.¹⁹⁻²¹

In order to prove pharmacology of new compounds in development for the treatment of mitochondrial dysfunction, *in vivo* biomarkers, that reflect mitochondrial function, are necessary. Ideally, mitochondrial function of the affected part of the brain is measured, which is currently technically not yet possible. The best *in vivo* alternative available, measuring the bio-energetic state of the visual cortex, indirectly measures mitochondrial function and has not yet been correlated to robust *in vitro* or *ex vivo* methods, unlike muscle mitochondrial function, for which these correlations were previously described.²² However, it is not known how central and peripheral mitochondrial function relate to each other. In this study we explore the relationship between peripheral mitochondrial function in the calf muscle (*in vivo*) and circulating lymphocytes (*ex vivo*), central bio-energetics in the visual cortex (*in vivo*) and clinical function in a cohort of manifest HD patients.

MATERIAL AND METHODS

Participants

All patients were participants in a randomized, double blind, placebo controlled study with the small peptide SBT-020 from Stealth Biotherapeutics (<https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003730-25/nl>). The results of this study have not yet been accepted for publication. The interventional study consisted two parts: Part 1, which was a 7-days multiple, ascending dose study and Part 2, which was a 28-days multiple dose study with the highest tolerable dose from Part 1. There was a washout period of at least 1 month between both parts. Patients were re-randomized before entering Part 2. The data used in this manuscript were from the baseline measurement before dose administration in Part 2. Data from all patients were used in this comparative study. The main inclusion criteria were: DNA confirmed diagnosis of HD with a CAG-repeat expansion of 36 or more; Total Motor Score (TMS) of 5 or more and Total Functional Capacity Score (TFC) of 6 or more on the Unified Huntington Disease Rating Scale (UHDRS); absence of any significant comorbidity.

Medication with an effect on cognitive functioning (e.g. antidepressants) needed to be stable for at least 30 days before study enrolment. Medication with known mitochondrial toxicity (e.g. statins and metformin) were not allowed within 21 days before study enrolment until the end of the study period.

The study was approved by the independent ethics committee Stichting BEBO (Assen, the Netherlands) according to the principles of the Helsinki Declaration



under registration number NL59198.056.16, and informed consent was obtained from all subjects prior to study enrollment.

Mitochondrial function

Peripheral mitochondrial function (calf muscle)

Dynamic ^{31}P -MRS in skeletal muscle (i.e. the gastrocnemius muscle of the right leg) was performed at a field strength of 7 Tesla using a surface coil on a custom-built MRI-compatible pedal ergometer (made by the technical instrumentation division of the LUMC, Leiden, The Netherlands). The exercise ergometer was designed to allow the patients to perform isometric plantar flexion exercise by pressing against a foot pedal while lying in the supine position. The foot was strapped firmly to the exercise device using non-elastic Velcro straps proximal to the base of the fifth digit, and the knee was supported. The subject's lower extremity was secured to the MRI table with straps across the mid-thigh and mid-lower leg in order to isolate usage of the posterior calf muscles. The scanning protocol consisted of localizer sequences and the acquisition of a field map for shimming purposes. Thereafter, ^{31}P -MRS data was acquired before, during and after exercise with a time resolution of 2 s. Peak integrals of the inorganic phosphate (PI), phosphocreatine (PCR) and adenine triphosphate (ATP) signals were obtained using the JMRUI software package. The frequency difference between PCR and PI was used to calculate tissue pH. A pH of at least 6.8 was required for a reliable τPCR .²³

Peripheral mitochondrial function (circulating lymphocytes)

The mitochondrial membrane potential ($\Delta\Psi\text{m}$) is the major force driving protons across the inner membrane,^{24,25} which is in turn the central intermediate of aerobic energy production, and driving force of other physiological processes in mitochondria, such as Ca^{2+} uptake, antioxidant defence (NADPH generation at the transhydrogenase) or heat production of brown fat. The $\Delta\Psi\text{m}$ of a lymphocyte subset of live peripheral blood mononuclear cells (PBMCS) was assessed with flow cytometry as the ratio of fluorescent signals after treatment of the cells with the fluorescent dye JC-1.²⁶ Attracted by the positive charge of the inner mitochondrial space, accumulation of the dye leads to a change in

fluorescence ('green' to 'red') and a higher ratio of red to green corresponds to a higher $\Delta\Psi\text{m}$. Additionally, we determined the stressability of the mitochondria by treating the PBMCS *ex vivo* with two medications with mitotoxic properties (carvedilol and verapamil). The technical aspects of the methods can be found in the supplement.

Central bio-energetic state (visual cortex)


^{31}P -MRS of the brain was performed on a 3 Tesla whole-body MRI scanner (Philips Achieva, Best, The Netherlands). A custom-made 6-cm ^{31}P transmit/receive surface coil was used to detect signals from the visual cortex while limiting muscle contamination. Technical details of the method are described in the supplementary section. Using a checkerboard animation (a projection of alternating black and red lights), neurons in the visual cortex are being activated and this activity is measured by PI/PCR and PI/ATP ratios.¹⁷ The ratios are a direct marker for the bio-energetic state within the mitochondria.²⁷⁻³³ In healthy controls, the ratios increase during visual stimulation, whereas in HD patients the ratios stay the same, which reflects the difference in bio-energetics between the two groups.¹⁷

Unified Huntington's Disease Rating Scale (UHDRS)

The UHDRS is a clinical assessment scale, which is used as the gold standard for motor, cognitive, behavioural capacity and function of HD patients. The method is described in detail elsewhere.³⁴ The UHDRS was performed by one of three certified physicians to assess the sub-scores total motor functioning (TMS) and the total functional capacity (TFC).^{34,35} A higher TMS indicates increased motor symptoms and a lower TFC indicates increased functional disability. Apart from assessing drug efficacy, the scores were used as inclusion criteria to ensure that patients were symptomatic, but could still function well enough to participate.

Statistical methods

The statistical analysis was performed using SPSS v25. All missing or incomplete data were treated as such. Pearson correlation coefficients were used to assess correlation between parameters. The threshold for statistical significance was set at $p\text{-value} < 0.05$.



RESULTS

Demographics

A total of 23 patients (10 females and 13 males, Table 6.1) with manifest HD (TMS ranged 5-53 ; TFC ranged 6-11) were enrolled in the study, with a mean age of 47.6 years (range 20 to 64 years) and on average HD-related complaints for 7.7 years (ranged 1 to 27 years).

Mitochondrial function

In vivo mitochondrial function was assessed in the calf muscles (peripheral) and bio-energetics in the visual cortex (central) using ³¹P-MRS. A detailed overview of the results is displayed in Supplementary Table 6.3.

Mitochondrial function in skeletal muscle

The mean τ_{PCR} in calf muscle was 39.5 seconds (SD 8.8, min 26.3, max 55.4 seconds). A longer duration for the PCR signal to return to baseline after exercise reflects a lower mitochondrial function.³⁶

Ex vivo mitochondrial health of lymphocytes

Lymphocytes were assessed for mitochondrial health by measuring the percentage of dysfunctional cells, the absolute membrane potential $\Delta\Psi_m$ and the membrane potential collapse induced by carvedilol and verapamil. The average percentage of dysfunctional lymphocytes was 3.6% (range 0.3-23.5%) and the average $\Delta\Psi_m$ was 3518 (range 802-6082). The average IC₅₀ for induced membrane potential collapse was 0.27 mmol for carvedilol (range 0.13-0.48 mmol), and 0.54 mmol for verapamil (range 0.34-0.78 mmol).

Bio-energetic state in the visual cortex

The bio-energetics in the visual cortex was assessed by determining different ratios in energy metabolism in rest, during and after visual stimulation (see Figure 6.1). The ratios are listed in Supplementary Table 6.4. During rest, the mean PI/PCR ratio was 0.21 (SD 0.03, min 0.16, max 0.28) and the mean PI/ATP ratio was

0.19 (SD 0.03, min 0.12, max 0.23). The ratios did not significantly differ when measured before, during or after the visual stimulation, which is in line with literature. Importantly, in healthy volunteers, the ratios would increase during visualization and decrease again during recovery).¹⁷

Correlation peripheral versus central mitochondrial bio-energetics

None of the variables for peripheral mitochondrial capacity or health (³¹P-MRS of skeletal muscle and collapse of $\Delta\Psi_m$ in lymphocytes after titration with carvedilol or verapamil) showed correlation with central bio-energetics or clinical function. PI/PCR and PI/ATP ratios before visual stimulation showed a significant correlation to clinical function (TMS only), with an *r* of -0.45 (*p* = 0.02) to -0.48 (*p* = 0.03), respectively. The ratios during and after visual stimulation did not correlate to clinical function (TMS or TFC). Pearson correlation coefficients and *p*-values are shown in Table 6.2 and Figure 6.2.

Post hoc subgroup analysis

A post hoc analysis was performed in patients (*n*=11) with the highest CAG repeat number to investigate if mitochondrial dysfunction would be worse with higher disease load (Table 6.3). The subgroup consisted of the 11 patients with the highest CAG repeat number (range 43-60). TMS strongly correlated to PI/ATP ratio at rest (*r* = -0.76, *p* = 0.006) and PI/PCR ratio at rest (*r* = -0.66, *p* = 0.03). TFC correlated to PI/ATP ratio at rest (*r* = 0.63, *p* = 0.04) and PI/PCR ratio at rest (*r* = 0.68, *p* = 0.02). TFC also correlated to the difference in PI/PCR before and during activation (*r* = 0.67, *p* = 0.03). Mitochondrial function in muscle did not correlate to bio-energetic state in the visual cortex.

DISCUSSION

Central mitochondrial function based on the bio-energetic state in the visual cortex was not correlated to peripheral mitochondrial function in calf muscle. There was a moderate correlation between central mitochondrial bio-energetics and Total Motor Score within the full patient cohort. The data imply that a larger HD-related disability (higher TMS) correlated to a worse bioenergetic profile (lower



PI/PCR and PI/ATP ratios) in the visual cortex. When selecting patients with the highest CAG repeat number, the correlation between central mitochondrial capacity and Total Motor Score was strong, with a moderate correlation between central mitochondrial bio-energetics and Total Functional Capacity.


To our knowledge this is the first study, comparing *in vivo* central to peripheral mitochondrial function in HD patients. Apart from the striatal area, mitochondrial dysfunction in HD patients has been reported in both calf muscle (Saft *et al.*) as well as in the visual cortex (Mochel *et al.*).^{16,17} However, we did not observe a correlation between the mitochondrial function in skeletal muscle and circulating lymphocytes and bioenergetics in the visual cortex. When comparing mitochondrial function to clinical function, we also observed a difference between peripheral and central function. We observed a significant negative correlation between TMS vs PI/PCR ratio ($r = -0.45$) and vs PI/ATP ratio ($r = -0.48$). In the patients with a higher CAG repeat number than the median, the correlation between TMS vs PI/PCR ratio ($r = -0.66$) and vs PI/ATP ratio ($r = -0.76$) was stronger, in addition to a significant positive correlation between TFC vs PI/PCR ratio ($r = 0.68$) and vs PI/ATP ratio ($r = 0.63$). These data show that patients with a higher degree of HD-related pathology have a lower mitochondrial function in the visual cortex. No correlations between clinical function and peripheral mitochondrial function were observed.

We expected a correlation between central and peripheral mitochondrial function, because MHTT is ubiquitously present in mitochondria of HD patients. However, it is known that mitochondrial function is affected differently in different tissues (reviewed by Polyzos *et al.*).² In postmortem brain samples, complex II, III and IV deficiencies have been observed, whereas in skeletal muscle and platelets complex I is more affected. Even within the brain, there are differences between more and less affected regions: using spectrophotometric assays, ETC enzymes were impaired in the basal ganglia of HD brains, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum).³⁷ In the most affected region of the HD brain, the striatum, complex II–III activity were markedly reduced in both caudate (–29%), while complex II–III (–67%), and IV (–62%) are altered in the putamen.³⁷ When combined with the fact that mitochondrial disturbances are only universally observed late in the disease progression of mouse models,³⁸ it is plausible that mitochondrial dysfunction is a consequence of a metabolic disturbance, rather than the cause. Additionally, the regional specificity implies that mitochondrial dysfunction develops in response to its changing environment. It is unfortunately not known what this might be. However, supplementing essential

substrates to the Krebs cycle through administration of triheptanoin – a long fatty acid, which is metabolized into acetyl-CoA and propionyl-CoA – in a pilot study led to the normalization of bioenergetics in the brain of HD patients.¹⁹ A phase 2 study with triheptanoin for efficacy on clinical function measured by the UHDRS is currently running. Mitochondrial dysfunction might not be the direct cause of HD, but could potentially be used to alleviate symptoms.

In other neurodegenerative disorders, mitochondrial dysfunction also plays a role in the pathophysiology via a toxic accumulation of misfolded proteins (hyperphosphorylated tau and Ab plaques in AD, alpha-synuclein in PD, and MSOD1 in ALS). The same pattern between central and peripheral mitochondrial function has been observed. In a study comparing mitochondrial function in brain, skeletal muscle and platelet homogenates from idiopathic PD patients³⁹, mitochondrial dysfunction was found to be part of the pathophysiology of PD (complex I deficiency), but limited to the substantia nigra, with normal mitochondrial function in skeletal muscle and platelets. In a study on mitochondrial dysfunction in post-mortem brains of AD, complex II, III and IV were reduced in activity in the temporal, parietal, entorhinal cortex and hippocampus, but succinate cytochrome c reductase was significantly reduced only in the parietal and temporal cortex.⁴⁰ Although mitochondrial dysfunction is a common phenomenon in neurodegenerative disorders, it is expressed differently. Inside the brain, the most affected areas differ between diseases, as well as the impairment of the mitochondrial respiratory chain complexes activity (complex I, III, and IV in AD; complex I and IV deficiency in PD; complex II, III, and IV deficiency in HD; and complex I, II, III, and IV deficiency in ALS). Although mitochondrial dysfunction plays an important role, the pathology of neurodegenerative disorders is likely multifactorial.

A reason for the discrepancy between peripheral mitochondrial function and clinical function may be that mitochondrial function in muscle tissue is more influenced by physical activity. It is known that a sedentary lifestyle is associated to a lower mitochondrial function in skeletal muscle in otherwise healthy elderly, which can be improved by increased physical activity.^{41,42} Exercise has also been shown to increase mitochondrial function in the muscle of HD patients.^{43,44} Given that patients with a higher disease severity are more prone to have a sedentary lifestyle due to physical disability, it is difficult to know how much muscle mitochondrial dysfunction is directly disease related and how much is physical activity dependent. Being physically active could boost mitochondrial function in skeletal muscle, but not influence mitochondrial bio-energetics in the striatum, resulting in a lack of correlation.



Improving clinical function in patients with HD and other neurodegenerative diseases, such as Parkinson's disease, has proven difficult due to the progressive nature of neurological pathology, but improving mitochondrial function can be used to show proof-of-pharmacology in an early stage of compound development. Both peripheral and central mitochondrial function measurements could be used, but for different reasons. Peripheral mitochondrial function (^{31}P -MRS of skeletal muscle) has the advantage of being better accessible than the brain and can be combined with other types of measurements (e.g. respirometry on muscle biopsy) and the mitochondrial membrane potential in lymphocytes has been explored as a systemic biomarker for diseases with mitochondrial dysfunction such as Alzheimer's disease, rheumatoid arthritis and diabetes type 2⁴⁵⁻⁴⁷, and as a tool to monitor mitotoxic drug effects, for example of anti-cancer drugs and volatile anesthetics.^{48,49} However, any pharmacodynamic effect in skeletal muscle or circulating lymphocytes might not correlate to the central nervous system and thus not informative when disease modifying is the primary aim of the study. On the other hand, central mitochondrial function (^{31}P -MRS of visual cortex) correlates to clinical function in HD patients and should therefore be used to evaluate pharmacology of compounds being developed for the disease modifying treatment of HD.

This study contains three limitations. First, the number of patients was relatively small, which needs to be considered when interpreting the results. Studies with larger cohorts are therefore needed to confirm the results. Second, caution is advised when comparing different aspects of mitochondrial function in different tissues. Earlier studies have separately investigated different aspects of mitochondrial function and have shown deficits. In this study we have combined these measurements within the same patients for the first time. Although we did not show any correlations between central and peripheral mitochondrial function, the complexity of mitochondrial dysfunction within the pathophysiology of HD warrants further research. Third, our ^{31}P -MRS setup included a phosphorous surface coil, which limited the measurements to the visual cortex. Currently, *in vivo* ^{31}P -MRS of the brain is an important way to gain insight into bioenergetics in HD patients. While measuring bioenergetics within the striatal area would in theory yield more relevant results to HD pathology, disturbances within the visual cortex have been described before.¹⁷ However, the results from this study should be interpreted with this caution in mind. Additionally, future studies should try to include the striatal area, if technologically possible.

In conclusion, we did not observe a correlation between peripheral and central mitochondrial function in a group of mild to moderate HD patients. Central, but not

peripheral, mitochondrial function correlated to clinical function. Mitochondrial function is a promising biomarker to evaluate disease-modifying compounds that improve mitochondrial function, but researchers should use central mitochondrial function instead of peripheral mitochondrial function to demonstrate proof-of-pharmacology of compounds intended as disease modifying.

Funding and acknowledgement

We would like to thank the HD patients for their participation in the study, The Dutch Huntington's Disease patient organization for their help with recruitment and the clinical staff of CHDR and the LUMC for facilitating this trial.


SUPPLEMENTARY TEXT

Technical details of the mitochondrial membrane potential measurements

The mitochondrial membrane potential ($\Delta\Psi\text{m}$) of live, circulating lymphocytes was assessed using a fluorescent dye (JC-1) and flow cytometry.²⁶ The dye is attracted to the positive charge of the proton gradient within the intermembrane space. When accumulation occurs, the dye aggregates and emits red fluorescence. In case of mitochondrial dysfunction, the $\Delta\Psi\text{m}$ is decreased and the dye stays in the cytosol as monomers, emitting green fluorescence. Cytometry was used to quantify the fluorescence. Using the ratio of the fluorescent signals, the $\Delta\Psi\text{m}$ was determined. A fraction of the lymphocytes was treated with the mitochondrial uncoupling agent carbonyl cyanide *m*-chlorophenyl hydrazine (CCCP), eliminating the proton gradient, to act as a positive control.

Gating strategy

The lymphocyte subset of the PBMCs is targeted based on the FSC and SSC (Figure 6.3, left panels). The positive control is used to target the dysfunctional lymphocytes, this gate is then copied to the sample (right panels). All the cells of the sample falling in this gate are dysfunctional and reported as a percentage of the parent population, the dysfunctional lymphocytes. The delta Psi was calculated as follows. The median fluorescence intensity (MFI) value for red (FL-2, PE-A B2-A) obtained without CCCP was divided by the MFI for green



(FL-1, FITC-A B1-A) without CCCP. In a second step, a correction for the positive control was performed. In particular, the ratio FL-2:FL-1 was calculated with the values obtained with the CCCP (positive control) and set as 100%. Finally, the value of the first ratio (without CCCP) was expressed as percentage of the second ratio (with CCCP).

$$\Delta\psi_m = \left(\frac{FL2}{FL1} / \frac{FL2_{CCCP}}{FL1_{CCCP}} \right) \times 100$$


Additionally, the mitochondria were additionally assessed by measuring the 'stressability' of lymphocytes after *ex vivo* titration of verapamil and carvedilol (two medications with mitotoxic effects).⁵⁰ We incubated freshly isolated lymphocytes from the patients with a concentration range (0mM, 0.125mM, 0.25, 0.5mM, 1mM and 2mM) of verapamil and carvedilol. With the titration curve, we calculated the half maximal inhibitory concentration (IC₅₀) values per timepoint, per mitotoxic compound.

Technical details of 31P-MRS of the visual cortex

A small sphere (10 mm in diameter) filled with water was placed below the coil along the coil axis to verify and adjust the positioning of the 31P RF coil on 1H images. An adiabatic pulse-acquire sequence (TR 2 s, flip angle 90°) was used to collect free induction decays (FIDs) for 4 minutes at rest (128 signals averaged), 8 minutes during visual activation (256 signals averaged), and 8 minutes after visual stimulation (256 signals averaged). Analysis of the 31P spectra using JMRUI allowed quantification of the following resonances: βATP, αATP, γATP, PCR, and PI, from which the ratios of PCR/ATP, PI/PCR, and PI/ATP were calculated as well as the pH. The spectra were analyzed in the time domain using AMARES in the JMRUI software package. AMARES allowed the inclusion of prior knowledge about relations between peaks (derived from the method of Mochel *et al.*).¹⁷

REFERENCES

- 1 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. *Cell*. 1993;72(6):971-983.
- 2 Polyzos AA, McMurray CT. The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease. *Mechanisms of ageing and development*. 2017;161(Pt A):181-197.
- 3 Quintanilla RA, Johnson GVW. Role of Mitochondrial Dysfunction in the Pathogenesis of Huntington's Disease. *Brain research bulletin*. 2009;80(4-5):242-247.
- 4 Hamilton J, Brustovetsky T, Brustovetsky N. Oxidative metabolism and Ca(2+) handling in striatal mitochondria from YAC128 mice, a model of Huntington's disease. *Neurochemistry international*. 2017;109:24-33.
- 5 Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N. Ca(2+) handling in isolated brain mitochondria and cultured neurons derived from the YAC128 mouse model of Huntington's disease. *Journal of neurochemistry*. 2015;134(4):652-667.
- 6 Brustovetsky N. Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling. *Molecular neurobiology*. 2016;53(5):2944-2953.
- 7 Pickrell AM, Fukui H, Wang X, Pinto M, Moraes CT. The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2011;31(27):9895-9904.
- 8 Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 1993;13(10):4181-4192.
- 9 Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. *Proceedings of the National Academy of Sciences of the United States of America*. 1995;92(15):7105-7109.
- 10 Khalil B, El Fissi N, Aouane A, Cabirol-Pol MJ, Rival T, Lievens JC. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. *Cell death & disease*. 2015;6:e1617.
- 11 Cannon JR, Tapias VM, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson's disease. *Neurobiology of disease*. 2009;34(2):279-290.
- 12 Orr AL, Li S, Wang CE, et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2008;28(11):2783-2792.
- 13 Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, Li XJ. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2003;23(6):2193-2202.
- 14 Song W, Chen J, Petrilli A, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. *Nature medicine*. 2011;17(3):377-382.
- 15 Yano H, Baranov SV, Baranova OV, et al. Inhibition of mitochondrial protein import by mutant huntingtin. *Nat Neurosci*. 2014;17(6):822-831.
- 16 Saft C, Zange J, Andrich J, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. *Movement disorders: official journal of the Movement Disorder Society*. 2005;20(6):674-679.
- 17 Mochel F, N'Guyen TM, Deelchand D, et al. Abnormal response to cortical activation in early stages of Huntington disease. *Movement disorders: official journal of the Movement Disorder Society*. 2012;27(7):907-910.
- 18 Sawa A, Wiegand GW, Cooper J, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. *Nature medicine*. 1999;5(10):1194-1198.
- 19 Adanyeguh IM, Rinaldi D, Henry PG, et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. *Neurology*. 2015;84(5):490-495.
- 20 Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. *Annals of the New York Academy of Sciences*. 2010;1201:96-103.
- 21 Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. *Experimental neurology*. 2004;188(2):491-494.
- 22 Lanza IR, Bhagra S, Nair KS, Port JD. Measurement of human skeletal muscle oxidative capacity by 31P-MR spectroscopy: a cross-validation with in vitro measurements. *Journal of magnetic resonance imaging: JMIR*. 2011;34(5):1143-1150.
- 23 van den Bogaard SJ, Dumas EM, Teeuwisse WM, et al. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. *Journal of neurology*. 2011;258(12):2230-2239.
- 24 Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. *Biochemical Journal*. 2011;435(2):297-312.
- 25 Nicholls DG. Mitochondrial membrane potential and aging. *Aging cell*. 2004;3(1):35-40.
- 26 Cossarizza A, Salvio S. Flow cytometric analysis of mitochondrial membrane potential using JC-1. *Current protocols in cytometry*. 2001;Chapter 9:Unit 9.14.



27 Chance B, Leigh JS, Jr., Clark BJ, et al. Control of oxidative metabolism and oxygen delivery in human skeletal muscle: a steady-state analysis of the work/energy cost transfer function. *Proceedings of the National Academy of Sciences of the United States of America*. 1985;82(24):8384-8388.

28 Hands LJ, Bore PJ, Galloway G, Morris PJ, Radda GK. Muscle metabolism in patients with peripheral vascular disease investigated by ³¹P nuclear magnetic resonance spectroscopy. *Clinical science (London, England: 1979)*. 1986;71(3):283-290.

29 Suzuki E, Kashiwagi A, Hidaka H, et al. ¹H- and ³¹P-magnetic resonance spectroscopy and imaging as a new diagnostic tool to evaluate neuropathic foot ulcers in Type II diabetic patients. *Diabetologia*. 2000;43(2):165-172.

30 Taylor DJ, Bore PJ, Styles P, Gadian DG, Radda GK. Bioenergetics of intact human muscle. A ³¹P nuclear magnetic resonance study. *Molecular biology & medicine*. 1983;1(1):77-94.

31 Greenman RL, Panasyuk S, Wang X, et al. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. *Lancet*. 2005;366(9498):1711-1717.

32 Wiener DH, Maris J, Chance B, Wilson JR. Detection of skeletal muscle hypoperfusion during exercise using phosphorus-31 nuclear magnetic resonance spectroscopy. *Journal of the American College of Cardiology*. 1986;7(4):793-799.

33 Zochodne DW, Thompson RT, Driedger AA, Strong MJ, Gravelle D, Bolton CF. Metabolic changes in human muscle denervation: topical ³¹P NMR spectroscopy studies. *Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine*. 1988;7(4):373-383.

34 Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. *Movement disorders: official journal of the Movement Disorder Society*. 1996;11(2):136-142.

35 Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. *Neurology*. 1979;29(1):1-3.

36 Walter G, Vandenborne K, McCully KK, Leigh JS. Noninvasive measurement of phosphocreatine recovery kinetics in single human muscles. *The American journal of physiology*. 1997;272(2 Pt 1):C525-534.

37 Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. *Annals of neurology*. 1997;41(5):646-653.

38 Polyzos A, Holt A, Brown C, et al. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. *Human molecular genetics*. 2016;25(9):1792-1802.

39 Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. *Brain: a journal of neurology*. 1992;115 (Pt 2):333-342.

40 Reichmann H, Flörke S, Hebenstreit G, Schrubar H, Riederer P. Analyses of energy metabolism and mitochondrial genome in post-mortem brain from patients with Alzheimer's disease. *Journal of neurology*. 1993;240(6):377-380.

41 Andreux PA, van Diemen MPJ, Heezen MR, et al. Mitochondrial function is impaired in the skeletal muscle of pre-frail elderly. *Scientific reports*. 2018;8(1):8548.

42 Lanza IR, Nair KS. Muscle mitochondrial changes with aging and exercise. *The American journal of clinical nutrition*. 2009;89(1):467s-471s.

43 Mueller SM, Gehrig SM, Petersen JA, et al. Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients. *Orphanet journal of rare diseases*. 2017;12(1):184.

44 Mueller SM, Petersen JA, Jung HH. Exercise in Huntington's Disease: Current State and Clinical Significance. *Tremor and other hyperkinetic movements (New York, NY)*. 2019;9:601.

45 Moodley D, Mody G, Patel N, Chuturgoon AA. Mitochondrial depolarisation and oxidative stress in rheumatoid arthritis patients. *Clinical biochemistry*. 2008;41(16-17):1396-1401.

46 Leuner K, Schulz K, Schutt T, et al. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. *Molecular neurobiology*. 2012;46(1):194-204.

47 Khan S, Raghuram GV, Bhargava A, et al. Role and clinical significance of lymphocyte mitochondrial dysfunction in type 2 diabetes mellitus. *Translational research: the journal of laboratory and clinical medicine*. 2011;158(6):344-359.

48 Salimi A, Roudkenar MH, Seydi E, et al. Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes. *Cancer investigation*. 2017;35(3):174-186.

49 Loop T, Dovi-Akue D, Frick M, et al. Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. *Anesthesiology*. 2005;102(6):1147-1157.

50 Finsterer J, Zarrouk Mahjoub S. Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders. *Expert opinion on drug metabolism & toxicology*. 2012;8:71-79.

TABLE 1 Demographics. Demographics and baseline values for the UHDRS sub-scores and the PCR recovery time of ³¹P-MRS of the calf muscle.

	Mean	SD	Min	Max
Number of patients (n)	23			
Age (years)	47.6	9.2	20	64
Sex (% female)	43.5%			
BMI (kg/m2)	26.2	4.7	18.8	40.3
CAG repeat (number)	44.3	4.4	39	60
Age of disease onset (years)	40.6	9.7	19	59
Time since HD-related complaints (years)	7.7	6.7	1	27
UHDRS (score)				
• TMS	22.7	11.1	5	53
• TFC	8.4	1.6	6	11
τPCR (calf muscle, in s)	40.2	6.4	33.3	57.5

UHDRS = Unified Huntington's Disease Rating Scale, TMS = Total Motor Score, TFC = Total Functional Capacity, τPCR = PCR recovery time.

TABLE 2 Pearson correlations. Pearson correlations between mitochondrial and clinical function in all patients.

		CAG repeats	PCR rec time	PCR/ATP ratio	PI/ATP ratio	PI/PCR ratio	TMS	TFC
CAG repeats	R	1	.334	-.325	-.158	.003	.283	-.178
	Sig. (2-tailed)		.120	.130	.472	.990	.190	.416
PCR Rec Time	R	.334	1	-.048	-.310	-.336	.386	-.252
	Sig. (2-tailed)	.120		.828	.151	.117	.069	.246
PCR/ATP ratio	R	-.325	-.048	1	.529**	.028	-.106	.030
	Sig. (2-tailed)	.130	.828		.009	.901	.629	.891
PI/ATP ratio	R	-.158	-.310	.529**	1	.860**	-.449*	.224
	Sig. (2-tailed)	.472	.151	.009		.000	.032	.304
PI/PCR ratio	R	.003	-.336	.028	.860**	1	-.478*	.276
	Sig. (2-tailed)	.990	.117	.901	.000		.021	.202
TMS	R	.283	.386	-.106	-.449*	-.478*	1	-.532**
	Sig. (2-tailed)	.190	.069	.629	.032	.021		.009
TFC	R	-.178	-.252	.030	.224	.276	-.532**	1
	Sig. (2-tailed)	.416	.246	.891	.304	.202	.009	

* Correlation is significant at the 0.05 level (2-tailed) / ** Correlation is significant at the 0.01 level (2-tailed).



TABLE 3 Post hoc analysis. Pearson correlations between mitochondrial and clinical function in the 11 patients with highest CAG repeat number.

		CAG repeats	TMS	TFC	PCR rec time	PCR/ATP ratio	PI/ATP ratio	PI/PCR ratio
CAG repeats	R	1	.070	-.266	-.619*	-.540	-.309	.014
	Sig. (2-tailed)		.838	.429	.042	.086	.355	.968
TMS	R	.070	1	-.550	.186	.131	-.174	-.317
	Sig. (2-tailed)	.838		.080	.583	.700	.608	.342
TFC	R	-.266	-.550	1	-.116	-.165	-.143	-.029
	Sig. (2-tailed)	.429	.080		.735	.627	.675	.932
PCR rec time	R	-.619*	.186	-.116	1	.643*	.186	-.233
	Sig. (2-tailed)	.042	.583	.735		.033	.584	.491
PCR/ATP ratio	R	-.540	.131	-.165	.643*	1	.593	.023
	Sig. (2-tailed)	.086	.700	.627	.033		.054	.947
PI/ATP ratio	R	-.309	-.174	-.143	.186	.593	1	.816**
	Sig. (2-tailed)	.355	.608	.675	.584	.054		.002
PI/PCR ratio	R	.014	-.317	-.029	-.233	.023	.816**	1
	Sig. (2-tailed)	.968	.342	.932	.491	.947	.002	


* Correlation is significant at the 0.05 level (2-tailed) / ** Correlation is significant at the 0.01 level (2-tailed).

TABLE 4 Central and peripheral mitochondrial function. Results mitochondrial assessments (peripheral and central).

Mitochondrial function tests	Mean (SD)	SD	Min	Max
SKELETAL MUSCLE				
PCR recovery time after muscle exercise (in seconds)	39.5	8.8	26.3	55.4
LYMPHOCYTES				
Dysfunctional cells (%)	3.6	4.9	0.3	23.5
MMP (delta Psi)	3518.8	1542.2	801.9	6082.4
IC ₅₀ verapamil (mmol)	0.54	0.13	0.34	0.78
IC ₅₀ carvedilol (mmol)	0.27	0.09	0.13	0.46
VISUAL CORTEX				
PI/PCR ratio before visual stimulation	0.21	0.03	0.16	0.28
PI/ATP ratio before visual stimulation	0.19	0.03	0.12	0.23
PI/PCR ratio during visual stimulation	0.23	0.04	0.15	0.32
PI/ATP ratio during visual stimulation	0.20	0.05	0.11	0.31
PI/PCR ratio after visual stimulation	0.23	0.04	0.15	0.31
PI/ATP ratio after visual stimulation	0.20	0.03	0.15	0.27


MMP = mitochondrial membrane potential, Pi = inorganic phosphate, ATP = adenosine triphosphate, PCR = phosphocreatine, IC₅₀ = half maximal inhibitory concentration.

FIGURE 1 Central mitochondrial function. Central mitochondrial function, assessed by phosphorous MRS of the visual cortex before, during and after visual stimulation. Bio-energetics was expressed as the ratio between phosphate energy metabolites. As expected in HD patients, no significant change was observed between the before and during and during and after ratios.



Pi = inorganic phosphate, PCR = phosphocreatine, ATP = adenosine triphosphate.

FIGURE 2 A-E Pearson correlations. Scatter plots displaying correlations between A. mitochondrial function in calf muscle and mitochondrial bio-energetics in the visual cortex, B. mitochondrial health in lymphocytes and mitochondrial bio-energetics in the visual cortex, C. Total Motor Score and mitochondrial bio-energetics in the visual cortex, D. Total Motor Score and mitochondrial capacity in calf muscle and E. Total Motor Score and mitochondrial health in lymphocytes.



* $p < 0.05$.

FIGURE 3 Example of gating of peripheral blood mononuclear cells. Example of gating of peripheral blood mononuclear cells to determine the percentage of dysfunctional cells. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) causes mitochondria to uncouple and is used as a positive control for mitochondrial dysfunction. This area is then gated and used to estimate the percentage of dysfunctional cells within an unstained population of cells.

